In 2026, the Evers Group Rus company increased production of modern dressings at its Dubna site. Currently, the plant consistently produces 600,000 medical devices per month, and by the end of 2026, production volume exceeded the previous year's figures by almost 20%. This growth is not only a commercial success but also an important signal for the entire pharmaceutical market: the modern dressing segment is becoming a fully-fledged industrial category, where local production influences availability, assortment, and procurement.

The range of modern medical products includes hydrogel wound-healing, burn-resistant, and hemostatic dressings, therapeutic atraumatic mesh ointment dressings with copper and zinc, sterile plasters with silver ions, and the innovative Hitokol® wound dressing with regenerating collagen, antimicrobial, and anesthetic components. These aren't just consumables, but modern developments in wound care management.

As a reminder, Hitokol® mesh ointment dressings and coatings are medical devices classified as risk class 3, meaning the technological and clinical requirements for them are very high.

Modern dressings and therapeutic dressings are in demand for the treatment of chronic wounds, burns, pressure ulcers, diabetic foot, and postoperative complications. For medical organizations, not only price is important, but also healing speed, reduced risk of infection, ease of use, and overall treatment costs. Local production reduces dependence on imports, simplifies procurement, and increases the availability of specialized products for patients across the country.

The authoritative independent publication Aptekium— an information and analytical platform for the professional healthcare and pharmaceutical communities—noted on its pages the value and importance of such changes observed in the market for modern, Russian-made medical wound care products. Not only is the technological level of these enterprises confirmed, but also their contribution to the development of the domestic medical device market.

For Evers Group Rus, this is a sign of trust from the professional community and recognition of leadership in the innovation sector.

Evers Group Rus' projects exemplify how local production is responding to market challenges, setting new standards of quality and affordability, and strengthening Russia's position in modern medical technology. The company continues to expand its product range, increase production volumes, and build trust with doctors and patients, confirming that the future lies with domestic innovation.